Talipexole or pramipexole combinations with chloro-APB (SKF82958) in MPTP-induced hemiparkinsonian monkeys

European Journal of Pharmacology

Volumn 325, Issue 2-3, 1997, Pages 137-144

  Domino, Edward F ^a   Ni, Lisong ^a   Zhang, Huilei ^a   Kohno, Yasuko ^b   Sasa, Masashi ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Chloro APB; Dopamine D1 like receptor agonist; Dopamine D2 like receptor agonist; Monkey; MPTP induced hemiparkinsonism; Pramipexole; SKF 82958; Talipexole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; PRAMIPEXOLE; TALIPEXOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAND MOVEMENT; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; MONKEY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

ANIMALS; ANTIPARKINSON AGENTS; AZEPINES; BASAL GANGLIA DISEASES; BEHAVIOR, ANIMAL; BENZAZEPINES; BENZOTHIAZOLES; DOPAMINE AGENTS; DOPAMINE AGONISTS; DRUG INTERACTIONS; FEMALE; MACACA NEMESTRINA; MPTP POISONING; PARKINSON DISEASE, SECONDARY; SLEEP; THIAZOLES;

EID: 0030965921     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)00129-5     Document Type: Article

References (38)

1. 2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys, Jpn. J. Pharmacol. 67, 117.
2. Andén, N.-E., K. Golembiowska-Nikitin and U. Thornström, 1982, Selective stimulation of dopamine and noradrenaline autoreceptors by B-HT 920 and B-HT 933, respectively, Naunyn-Schmiedeberg's Arch. Pharmacol. 321, 100.
3. Andén, N.-E., H. Nilsson, E. Ros and U. Thornström, 1983, Effects of B-HT 920 and B-HT 933 on dopamine and noradrenal autoreceptors in the rat brain, Acta Pharmacol. Toxicol. 52, 51.
4. Bankiewicz, K.S., E.H. Oldfield, C.C. Chiueh, J.L. Doppman, D.M. Jacobowitz and I.J. Kopin, 1986, Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Life Sci. 39, 7.
5. 2-like (N-0923) agonist combination in the MPTP monkey model of hemiparkinson's disease, Brain Res. Bull. 42 (in press).
6. 2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys, J. Pharmacol. Exp. Ther. 264, 221.
7. 2 receptors in MPTP-induced hemiparkinsonian monkeys, J. Pharmacol. Exp. Ther. 265, 1387.
8. 2 agonists, p. 67. Abstracts Michigan Chapter Soc. Neurosci., 26th Annual Meeting, Ann Arbor, MI, May 12.
9. Hinzen, D., O. Hornykiewicz, W. Kobinger, L. Pichler, C. Pifl and G. Schingnitz, 1986, The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment, Eur. J. Pharmacol. 131, 75.
10. Hoffmann, W.E., M.W. Smith and M.F. Piercey, 1995, #33 Electrophysiological evidence associating limbic preference with pramipexole, a D3-preferring dopamine agonist, p. 70. Abstracts Michigan Chapter Soc. Neurosci., 26th Annual Meeting, Ann Arbor, MI, May 12.
11. Honma, M., A. Matsuo, T. Yabe, J. Nishikawa, Y. Tsunenari, A. Kast and K. Kohei, 1993, The toxicology of talipexole in rats, Oyo Yakuri/Pharmacometrics 46, 383.
12. 2) in cynomolgus monkeys, Oyo Yakuri/Pharmacometrics 46, 401.
13. Irifune, M., M. Nomoto and T. Fukuda, 1993, Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets, Eur. J. Pharmacol. 238, 235.
14. Irifune, M., M. Nomoto and T. Fukuda, 1994, Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-DOPA and as chronic treatment, Eur. J. Pharmacol. 264, 117.
15. Kast, A., H. Ganz and W. Frölke, 1993, The oral toxicology of talipexole in rhesus monkeys, Oyo Yakuri/Pharmacometrics 45, 545.
16. 2-adrenoceptor subtypes: selectivity of various agonists and relative distribution of receptors as determined in rats, Eur. J. Pharmacol. 73, 313.
17. Kohno, Y., Y. Kitamura, M. Nakazawa and Y. Nomura, 1996a, The effects of talipexole on central monoamine receptors and metabolism in rats, with special reference to its effects on dopaminergic systems, Pharmacometrics (Jpn.) 52, 233.
18. Kohno, Y., S. Shibata, M. Ohno and S. Watanabe, 1996b, Electroencephalographic study on sedative effects of talipexole, a novel antiparkinsonian drug, in rats with chronic electrode implants, Pharmacometrics (Jpn.) 51, 45.
19. 2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum, Eur. J. Pharmacol. 319, 197.
20. 2 receptor agonist, on striatal neurons in rats, Neuropsychopharmacology 10, 141S.
21. Matsubayashi, H., T. Amano, Y. Hongjing, Y. Kohno and M. Sasa, 1995, Action of intravenously administered talipexole on the rat striatal neurons receiving excitatory input from nigral dopamine neurons, Psychopharmacology 120, 369.
22. Mierau, J., 1995, Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's disease, Clin. Neuropharmacol. 18 (Suppl. 1), S195.
23. 2 receptor agonist, Eur. J. Pharmacol. 215, 161.
24. 4 receptors, Eur. J. Pharmacol. 290, 29.
25. Murray, A.M. and J.L. Waddington, 1989, The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction, Eur. J. Pharmacol. 160, 377.
26. Nakanisi, T., H. Kowa, Y. Mizuno and N. Yanagisawa, 1993, The clinical evaluation of B-HT 920 (talipexole hydrochloride) in Parkinson's disease, Clin. Eval. 21, 59.
27. 3 receptor blocking properties of the antiparkinsonian agent, talipexole, Gen. Pharmacol. 27, 779.
28. 1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset, Neurosci. Lett. 57, 37.
29. 2 agonist LY 171555 in the MPTP-treated marmoset, Neurosci. Lett. 93, 275.
30. O'Boyle, K.M., D.E. Gaitanopoulos, M. Brenner and J.L. Waddington, 1989, Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor, Neuropharmacology 28, 401.
31. Pfeiffer, F.R., J.W. Wilson, J. Weinstock, G.Y. Kuo, P.A. Chambers, K.G. Holden, R.A. Hahn, J.R. Wardell Jr., A.J. Tobia, P.E. Setler and H.M. Sarau, 1982, Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1 H-3-benzazepines, J. Med. Chem. 25, 352.
32. Pichler, L. and W. Kobinger, 1981, Centrally mediated cardiovascular effects of B-HT 960 (6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo- [4,5-d]-azepin dihydrochloride) a hypertensive agent of the 'clonidine type', J. Cardiovasc. Pharmacol. 3, 269.
33. The Guide for the Care and Use of Laboratory Animals, 1985, Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission of Life Sciences, National Research Council, pp. 1-83, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH Publication #86-23, Superintendent of Documents, U.S. Government Printing Office, Washington, DC (Revised).
34. The Virus Working Group, 1988, Guidelines for prevention of herpes virus simiae (B virus) infection in monkey handlers, J. Med. Primatol. 17, 77.
35. 2 agonist, of caudate nucleus neurons activated by nigral stimulation, Life Sci. 54, 957.
36. 2 receptor agonists on motor behavior of MPTP-lesioned monkeys. A preclinical model of Parkinson's disease. Thesis (Department of Experimental Neurology. Vrije Universiteit, Amsterdam).
37. 1 agonist, SKF 81,297, stimulates motor behaviour of MPTP lesioned monkeys, Eur. J. Pharmacol. 235, 143.
38. Yamada, K., M. Nagashima, H. Kimura, S. Matsumoto and T. Furukawa, 1990, Possible involvement of differing classes of dopamine D-2 receptors in yawning and stereotypy in rats, Psychopharmacology 100, 141.